Abstracts

891 – Re-Examining InSTI Effects on Weight Gain Among Treatment-Naive People With HIV in North America

Background Prior analyses highlighted the association between starting INSTI-based antiretroviral therapy (ART) and weight gain among treatment-naïve people with HIV (PWH) in the North American AIDS Cohort Collaboration on Research & Design (NA-ACCORD). However, it is unclear whether observed relative weight gain after INSTI initiation reflected weight-suppressive effects of older NNRTIs or confounding due to…

889 – Multimorbidity and Quality of Life Among Older People Living With HIV in Urban Tanzania

Background Approximately one-third of Tanzanians living with HIV are aged ≥50. Aging persons living with HIV (PLWH) are at a higher risk of multi-morbidities compared to older persons without HIV. Multi-morbidities can have a significant negative impact on quality of life (QOL). This study assessed the distribution of geriatric and medical comorbidities and their association with…

939 – Distinct Proinflammatory/Proangiogenetic Signatures Distinguish Children With Long COVID

Background Recent proteomic studies have documented that Long Covid in adults is characterized by a pro-inflammatory signature with thromboinflammation. However, if similar events happen also in children with Long Covid has never been investigated. Methods We performed proteomics analyses of blood plasma from pediatric patients younger than 19 years of age Long Covid and sex-…

830 – BMI Is a Poor Surrogate for Excess Visceral Adiposity and Cardiovascular Risk in Persons With HIV

Background Recent studies demonstrate substantial weight gain among people with HIV (PWH) starting modern antiretroviral (ART) regimens, as well as a high prevalence of obesity among those on long-term treatment. As a result, routine body mass index (BMI) measurements have been proposed to assess cardiovascular (CV) and other comorbid illness risk. However, prior studies show…

898 – Incident Diabetes Among People With HIV After Switching to Integrase Strand Transfer Inhibitors

Background Initiation of integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy (ART) is associated with weight gain and diabetes mellitus (DM) among ART-naïve people with HIV (PWH). However, most are ART-experienced and may switch to an INSTI-based ART from a different antiretroviral regimen. We aimed to estimate the risk of incident DM associated with switching from…

758 – Evaluation of Different Noninvasive Models in Assessing Lean MAFLD Among PLWH

Background This study aimed to investigate prevalence of lean metabolic associated fatty liver disease (lean MAFLD) in people living with HIV(PLWH) and the value of ten diagnostic models in MAFLD among PLWH. Methods Transient Elastography (Fibroscan), Controlled attenuation parameter (CAP) and ultrasonography were performed among PLWH. MAFLD was defined by the 2024 revised edition of the…

682 – Outcomes of LAI ART for People With Detectable HIV Viremia in the NYC Public Healthcare System

Background Long-acting injectable cabotegravir/rilpivirine (LAI CAB/RPV) has changed the landscape of antiretroviral therapy (ART) by creating an alternative to daily oral ART. While FDA approval is currently limited to individuals with viral load suppression (VLS), there is growing evidence that CAB/RPV may also benefit virally unsuppressed patients who face adherence challenges taking oral ART. Our study…

675 – Outcomes on Cabotegravir + Rilpivirine in Suppressed People With HIV (PWH) in TRIO Health US Cohort

Background Cabotegravir+Rilpirivine (CAB+RPV) is the first complete long-acting injectable antiretroviral therapy (ART) for the treatment of HIV for ART-experienced PWH with undetectable viral load (VL <50 copies/mL [cpm]). This study examined the utilization and effectiveness of CAB+RPV in real-world settings in the US. Methods ART-experienced adults with undetectable VL at initiation who received ≥1 CAB+RPV injection…

776 – Performance Evaluation of the Xpert Hepatitis B Molecular Test Among Pregnant Women in Uganda

Background To prevent child-mother-to-child transmission of hepatitis B (HBV PMTCT), the World Health Organization recommends HBV screening among pregnant women, testing for HBV DNA, prophylactic antivirals, and hepatitis B birth dose vaccination to newborns. Uganda is utilizing its existing HIV platforms to integrate Hepatitis B services as part of the triple-elimination strategy. While HBV screening has improved,…

782 – Simulation Modeling of Hepatitis B Virus Disease Progression, Hepatitis Flares, and Functional Cure

Background Nearly 300 million people have chronic hepatitis B infection (HBV), which can result in hepatic complications (e.g., cirrhosis and hepatocellular carcinoma [HCC]) and mortality. Our objective was to develop and validate an HBV simulation model to examine disease progression, treatment, and cure.  Methods We developed an HBV simulation model with nine health states: HBV-uninfected;…